Introduction
============

Fibrosis is characterized by extracellular matrix (ECM) accumulation and often by a change in the quality of the ECM, as well as angiogenesis. It is a common pathological response to tissue insults such as hyperglycemia, dyslipidemia, and hypertension. This review will examine the extent and type of tissue fibrosis that occurs in experimental and human diabetes, with an emphasis on potential circulating and urinary predictors and markers of fibrosis in human diabetes. While the pathogenesis and nature of end-organ complications in type 1 and type 2 diabetes are similar, especially in glucose-dependent aspects of microvascular disease, where possible throughout the text the type of diabetes is referenced.

Fibrosis in tissues affected by diabetic complications
======================================================

Microvessels
------------

Long-standing diabetes leads to both structural and functional anomalies in the vasculature ([@b297]; [@b118]) which characterize micro- and macrovascular diabetic complications: retinopathy, nephropathy, cardiomyopathy, peripheral vascular disease, cerebrovascular disorders, and atherosclerosis. Firstly described by [@b231], extracellular matrix (ECM) alterations and basement membrane (BM) thickening have been documented as structural hallmarks in all target organs of diabetic complications ([@b21]; [@b257]). The morphological and biochemical disturbances of the ECM are directly related to a loss of function in target organs ([@b56]; [@b218]; [@b105]; [@b150]). ECM comprises an insoluble network of collagens, elastins, structural glycoproteins, proteoglycans-hyaluronans and integrins, which provide not only mechanical support for the cells, but also mediate complex interactions between the cells or between cells and the ECM of vascular tissues ([@b89]). EC matrices differ qualitatively and quantitatively from tissue to tissue and within various organs.

Diabetic retinopathy
--------------------

Expansion of ECM that occurs in diabetic complications can be due to increased synthesis of matrix proteins and/or an inhibition of ECM degradation. With respect to the increased synthesis of matrix, proteins that are normally present in these structures or proteins that are not present in normal tissue, or both, may be induced. Thus, collagen types I and IV as well as laminin and fibronectin are normal constituents of normal retinal vessels from large thick-walled vessels down to microvessels less than 10 microns in diameter, whilst types III and V collagen were seen to stain primarily the walls of the larger vessels. A preclinical hallmark of early diabetic retinopathy (DR) is the thickening of the capillary basement membrane (BM) resulting from increased production and/or decreased breakdown of collagen IV, laminin, fibronectin, and other proteins ([@b205]; [@b145]; [@b234]; [@b146]). In proliferative diabetic retinopathy (PDR), the BM of the new vessels and the epiretinal membranes show significantly increased amounts of types VI, VIII, XII, and XIV collagen, as well as perlecan, bamacan ([@b145]), fibronectin, tenascin ([@b107]), and vimentin ([@b96]). While not present in normal retina ([@b111]), type II collagen was found in epiretinal membranes (ERM) ([@b96]). A positive relationship was found between fibronectin expression and ERM proliferative activity ([@b107]). Downregulation of fibronectin synthesis could partially prevent retinal BM thickening along with a reduction of pericyte loss and acellular capillaries in animal model ([@b206]).

Diabetic renal disease
----------------------

Type IV collagen collagen, fibronectin and laminin, which are normal constituents of the mesangium and glomerular basement membrane (GBM), are increased in diabetic kidney disease ([@b120]; [@b150]; [@b121]; [@b296]; [@b285]; [@b193]; [@b162]). Accelerated matrix deposition (type IV collagen) can be present even in early stages of diabetic renal disease (microalbuminuria stages) in experimental models ([@b144]). In diabetic diffuse glomerulosclerosis deposition of collagen IV, V, laminin, and fibronectin is increased in the mesangial matrix and glomerular basement membranes ([@b170]; [@b257]), whilst in nodular glomerulosclerosis normal BM components are decreased or absent ([@b177]). Expressed only under pathological conditions, type I and III collagen appears in the late stages of glomerulosclerosis ([@b72]; [@b149]; [@b194]; [@b148]; [@b235]; [@b217]), and are associated with the development of Kimmelstiel-Wilson nodules rather than with the diffuse expansion of the mesangial matrix, which occurs in the early and moderately advanced stages of the disease. Decreased levels of proteoglycans (heparin sulphate, perlecan) found in diabetic kidney in the mesangial matrix, GBM, the endothelial and epithelial BM, and renal tubular cells have also been assigned a role in the development of diabetic micro- and macroalbuminuria ([@b217]). Interestingly, a substantial subset of type 2 diabetic patients, despite the presence of microalbuminuria or proteinuria, have normal glomerular structure with or without tubulointerstitial and/or arteriolar abnormalities ([@b58]).

Diabetic cardiomyopathy
-----------------------

Both types I and III collagen are present in normal and diseased myocardial tissue. Type I collagen is predominant in the myocardium, but type III is more specific to cardiac tissue ([@b15]; [@b292]; [@b38]). Myocardial biopsies from diabetic subjects revealed a significantly higher proportion of type III collagen compared with their nondiabetic counterparts, while the proportion of collagen type I did not differ between the groups ([@b228]). Responsible for the increased left ventricle (LV) mass ([@b267]), diffuse myocardial fibrosis has a distribution in both interstitium and perivascular sites ([@b195]; [@b174]; [@b68]; [@b39]; [@b267]). Extensive myocyte necrosis and replacement of contractile fibers by connective tissue are likely to account for depressed cardiac performance, at least in advanced stages of diabetic cardiomyopathy ([@b55]). It appears that hypertrophy of myocardial cells and myocardial interstitial fibrosis may be present even in mild hyperglycemia in diabetes ([@b174]).

Larger arteries
---------------

In animal models of type 2 diabetes it has been found that increased intimal proliferation and medial thickness as well as ECM deposition occur in vessels such as mesenteric arteries and aorta ([@b233]). Vascular remodeling and hypertrophy associated with augmented expression of dedifferentiation markers of vascular smooth muscle cells also occur in larger vessels like aorta ([@b269]). Fibronectin expression varied in different reports in large vessels ([@b65]). Proteoglycans (PGs) such as versican, biglycan, and decorin have been involved in diabetic nephropathy pathogenesis ([@b217]). PGs accumulate in developing atherosclerotic and restenotic lesions, and thus contribute to plaque burden and influence cellular and extracellular events associated with the pathogenesis of vascular lesions, such as migration and proliferation, lipid metabolism and retention, and thrombosis ([@b229]; [@b51]; [@b169]; [@b255]).

Nonalcoholic fatty liver disease
--------------------------------

Type 2 diabetic patients also have an increased risk for developing chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of conditions characterized histologically by excessive accumulation of hepatic fat in the absence of alcohol consumption. Obesity, type 2 diabetes, dyslipidemia, and hypertension contribute to the risk for liver disease and to disease progression. Two main histological patterns of NAFLD are described: fatty liver alone and nonalcoholic steatohepatitis (NASH). NASH is an increasingly recognized cause of liver-related morbidity and mortality ([@b8]; [@b215]; [@b30]), with about a quarter of patients progressing to serious liver sequelae, including end-stage liver disease and hepatocellular carcinoma ([@b23]; [@b191]). Those at highest risk include patients with significant hepatic necro-inflammation and fibrosis ([@b192]; [@b215]). Unlike other vascular beds, the normal hepatic sinusoids have no BM to become thickened. Sinusoidal (perisinusoidal) fibrosis with formation of BMs occurs in a variety of liver diseases, including chronic viral hepatitis, alcoholic hepatitis and NASH. In those diseases, the fibrosis is a result of the activation of the hepatic stellate cells with a phenotypic transition to collagen-producing myofibroblasts. Activated hepatic stellate cells are involved in the ECM degradation and remodeling that occur with fibrogenesis ([@b237]).

Effects of diabetes on regulators of ECM turnover
=================================================

Metabolic and hemodynamic induction of fibrosis by hyperglycemia
----------------------------------------------------------------

Chronic hyperglycemia is a main factor in the onset of microvascular diabetic complications in both type 1 and 2 diabetes, as strict glycemic control reduces end-organ complication incidence and rate of progression ([@b249]; [@b264]). This pathogenesis is shown schematically in [Figure 1](#fig1){ref-type="fig"}. Specific biochemical pathways linking hyperglycemia to microvascular changes have been proposed: increased glucose flux through the polyol pathway ([@b78]), nonenzymatic glycation of proteins ([@b22]), glucose autooxidation, and oxidative stress ([@b102]), hyperglycemic pseudohypoxia ([@b280]), enhanced activation of protein kinase C isoforms ([@b135]; [@b44]), and alteration in cell signaling pathways ([@b20]; [@b227]). As described in subsequent sections, experimental data support causative roles for hyperglycemia and these downstream biochemical pathways in causing alterations in ECM turn-over ([@b66]; [@b165]; [@b204]; [@b271]). Hyperglycemia can work through both metabolic and hemodynamic pathways to change growth factors and ECM turn-over. This is shown schematically in [Figure 2](#fig2){ref-type="fig"}.

![The linear pathway leading from insulin deficiency, through hyperglycemia to diabetes complications.](vhrm0403-575-01){#fig1}

![Schematic diagram indicating how hemodynamic and metabolic factors, and growth factors, can network to cause tissue damage. Inflammation and fibrosis occur variably in tissue at different stages of diabetes complications.](vhrm0403-575-02){#fig2}

### Advanced glycation end-products (AGEs)

Hyperglycemia is responsible for the presence of high levels of nonenzymatically produced AGEs in patients with diabetes ([@b73]). AGEs are able to stimulate directly the production of ECM. Nonenzymatic glycosylation of collagens produces cross-linkages and hence may produce physical alterations in the properties of the ECM. AGEs modification of matrix proteins is able to disrupt matrix-matrix and matrix-cell interactions, contributing to their profibrotic action. In addition, AGEs significantly interact with the renin-angiotensin system. AGEs play important roles in cell signaling by interacting with specific receptors, receptor for advanced glycation end products (RAGE), that link to the activation of adhesion molecules, proinflammatory cytokines and growth factors, thus contributing to the pathogenesis of diabetic complications ([@b152]; [@b158]). AGEs have extracellular effects, such as protein cross-linking, that appear to inhibit ECM degradation and promote the expansion of the glomerular mesangial matrix and BM in diabetic kidney disease. Drugs that either inhibit the formation of AGE or break AGE-induced cross-links have been shown to be renoprotective in experimental models of diabetic nephropathy ([@b63]).

### The renin-angiotensin-aldosterone system

The renin-angiotensin-aldosterone system (RAAS) is an important contributor to the pathogenesis of diabetic micro- and macrovascular complications by inducing various tissue responses, such as vasoconstriction, inflammation, oxidative stress, cell hypertrophy and proliferation, angiogenesis and fibrosis. RAAS effects can be locally generated in many organs ([@b184]; [@b161]; [@b270]; [@b54]; [@b13]).

Angiotensin II (Ang II), the main physiological effector molecule of RAAS, mediates fibrosis by stimulating the synthesis of ECM components ([@b112]; [@b75]; [@b19]) apoptosis/proliferation ([@b52]), infiltration of inflammatory cells, and the release of inflammatory cytokines and growth factors such as transforming growth factor (TGF)-β1 ([@b283]), monocyte chemoattractant protein (MCP)-1 ([@b207]), vascular endothelial growth factor (VEGF) ([@b178]), platelet derived growth factor (PDGF) ([@b164]), and connective tissue growth factor (CTGF) ([@b211]; [@b57]). Ang II is up-regulated under the diabetic conditions ([@b230]) and exerts its deleterious effects through the angiotensin type I receptor (AT1R). RAS blocking with either angiotensin converting enzyme inhibitors (ACEI) or angiotensin type 1 receptor blockers (ARB) has clearly demonstrated positive outcomes on diabetic complications, with benefits beyond those derived from lowering blood pressure. Thus ACEI and/or ARB treatment can slow the progression of diabetic renal disease ([@b250]; [@b90]), decrease cardiovascular events ([@b90]), may decrease retinopathy in T1DM ([@b32]) and improves diastolic dysfunction in diabetic patients ([@b117]).

Another component of the RAAS, aldosterone, plays also a role in the development of hypertension, endothelial dysfunction, vascular structure damage, proteinuria, myocardial fibrosis, collagen synthesis ([@b26]). Spironolactone, an aldosterone antagonist, associated to ACEI and/or ARB treatment may offer additional renoprotection in diabetic nephropathy ([@b216]; [@b219]; [@b266]).

Growth factors
--------------

Under normal circumstances ECM undergoes continuous synthesis and degradation and ECM turn-over is a requisite for normal structure and function of organs and tissues ([@b263]). ECM turn-over is characterized by a balance between matrix formation and matrix degradation. Factors that regulate ECM formation include multiple forms of growth factor such as such as TGF-β ([@b156]; [@b126]; [@b197]), CTGF ([@b259]; [@b261]; [@b158]; [@b180]; [@b143]), and insulin-like growth factor I (IGF-I), fibroblast growth factor (FGF), epidermal growth factor (EGF) and PDGF, ([@b136]; [@b256]; [@b48]; [@b200]; [@b187]). Enzymes responsible for ECM degradation and remodeling include the matrix metalloproteinases (MMPs) ([@b159], [@b157]; [@b41]), and serine proteases ([@b67]), as well as their respective tissue inhibitors, the TIMPs ([@b166]; [@b222]; [@b74]), and PAI-1 ([@b59]; [@b157]). These regulators of ECM will now be explored in detail in diabetic complications.

The important role of growth factors in the pathogenesis of diabetic long-term complications was suggested by their increased concentrations in target tissues ([@b286]; [@b253]; [@b201]; [@b265]). In diabetic nephropathy, IGF-I seems to be implicated in the earlier stages of the disease, while TGF-β and CTGF are involved both in the early and later stages, being responsible, at least in part, for ECM accumulation ([@b181]; [@b71]; [@b198]). VEGF and FGF play a pivotal role both in nonproliferative and proliferative retinopathy ([@b277]; [@b153]).

[Figure 3](#fig3){ref-type="fig"} indicates the main growth factors involved in diabetic complications, based on tissue levels measured in human and animal diabetes, and also on intervention studies mainly in animals. An excess of growth factor is implicated in tissues where fibrosis predominates, whereas a lack of growth factors occurs in diabetic neuropathy and wound healing.

![The major growth factors implicated in diabetes complications. The prosclerotic ones involved in human diabetic fibrosis are currently thought to be TGF-β and CTGF.](vhrm0403-575-03){#fig3}

### TGF-β

TGF-β is generally accepted to be the main pro-fibrotic factor in diabetic nephropathy. Several lines of experimental and clinical evidence support a major role for TGF-β in development of glomerulosclerosis and interstitial fibrosis in diabetes. Diabetic environment up-regulated TGF-β1 expression and bioactivity in glomerular mesangial cells and proximal tubule cells ([@b300], [@b298]; [@b225]). With the development of incipient diabetic nephropathy TGF-β mRNA increased in mesangial cells, podocytes and tubular epithelial cells. Progression to manifest diabetic nephropathy was associated with further increase in TGF-β mRNA, especially in the glomeruli ([@b272]). The kidney of a diabetic patient actually elaborates TGF-β1 protein into the circulation whereas the kidney of a nondiabetic subject extracts TGF-β1 from the circulation ([@b226]). Inhibition of TGF-β1 with neutralizing antibodies prevented glomerular enlargement, and attenuated the excess matrix expression by reducing type IV collagen and fibronectin mRNA ([@b224]; [@b299]).

Up-regulation of TGF-β protein was demonstrated in the myocardium of rodents with diabetic cardiomyopathy. ARB treatment reduced its expression and decreased cardiac fibrosis ([@b278]). TGF-β is also involved in liver fibrosis ([@b203]), by activating the hepatic stellate cells and inducing apoptosis of hepatocytes in liver injury ([@b175]). However, due to its important anti-proliferative and anti-inflammatory effects, TGF- β is not a suitable target for therapeutic intervention.

### CTGF

CTGF is another prominent growth factor in the pathogenesis of diabetic nephropathy. High glucose conditions, TGF-β, AGEs, RAS, TNF-α, mechanical strain or CTGF itself promote CTGF expression by mesangial cells ([@b271]; [@b163]; [@b198]; [@b261], [@b262]; [@b36]; [@b100]). CTGF can also be produced by podocytes ([@b201]), parietal epithelial cells ([@b265]) and proximal tubular cells (Wang et al 2001; [@b201]). In experimental type 1 and type 2 diabetes CTGF mRNA and protein was up-regulated in various organs: kidney, heart, liver, retina ([@b201]). Glomerular CTGF mRNA levels were found to be upregulated in diabetic patients with microalbuminuria as well as in overt nephropathy ([@b265]). In addition, CTGF mRNA levels were found to correlate with the degree of albuminuria ([@b4]). We have recently found that renal tubular CTGF protein by renal biopsy at 5 years predicts albuminuria at 10 years, in a diabetic baboon model of type 1 diabetes ([@b251]). The role of CTGF in DN pathogenesis in both type 1 and type 2 diabetes has been confirmed by a recent study showing that a CTGF antisense oligonucleotide may attenuate progression of nephropathy in mice ([@b81]). CTGF overexpression in podocytes was critically involved in diabetes-related GBM thickening ([@b201]). However, a site-specific downregulation of CTGF accompanied by a reduced VEGF-A mRNA in glomeruli from diabetic patients can be evidenced in DN and is a result of podocyte loss ([@b12]).

Relative abundance of myocardial mRNA for CTGF compared with brain natriuretic peptide (BNP) was positively correlated with diastolic dysfunction, myocardial fibrosis area, and procollagen type 1 mRNA expression in a rat pressure overload cardiac hypertrophy model. Exogenous BNP prevented the production of CTGF in cardiac myocytes ([@b125]).

CTGF has been shown to be up-regulated in the retina of diabetic rats ([@b253]). It appears that in diabetes CTGF expression shifts from microglia to microvascular pericytes ([@b129]). CTGF was also expressed in endothelial cells and myofibroblast in PDR membranes, and in myofibroblast in proliferative vitreoretinal membranes ([@b3]). CTGF is overexpressed in pericytes in the human diabetic retina, irrespective of changes related to clinical DR like vascular leakage ([@b129]). Overexpression of CTGF in cultured human aortic smooth muscle cells, a cell type closely related to pericytes and mesangial cells, induced apoptosis by activating caspase 3 ([@b92]).

In fibrotic liver, CTGF mRNA and protein are produced by hepatocytes, fibroblasts, myofibroblasts, hepatic stellate cells (HSCs), endothelial cells, and bile duct epithelial cells ([@b190]). Interestingly, whilst in HSCs CTGF was only marginally stimulated by TGF-β, in cultured hepatocytes it was strongly upregulated by TGF-β ([@b79]). CTGF could be reduced in liver by antisense RNA of CTGF recombinant or slicing through siRNA, which decreased activation of HSCs, prevented the upregulation of CTGF and TGF-beta1 gene expression and inhibited accumulation of connective tissue proteins in the liver ([@b69]; [@b147]).

Once induced, CTGF can up-regulate its own gene expression ([@b198]; [@b261]; [@b273]). It is also able to initiate changes in ECM composition: it increased expression of fibronectin ([@b273]; [@b211]; [@b279]) and enhanced fibronectin assembly into an insoluble matrix ([@b279]), increased in type IV ([@b295]), type III ([@b130]) and type I collagen production ([@b77]), and up-regulated integrins on the cell surface, facilitating the deposition and assembly of ECM proteins ([@b279]). Furthermore, CTGF caused induction of plasminogen activator inhibitor-1 ([@b273]), rearrangement of the actin cytoskeleton ([@b37]) and an increase in TIMP-1 with subsequent decrease in matrix degradation ([@b158]). CTGF also exerted a strong chemotactic effect on peripheral blood mononuclear cells *in vitro* ([@b34]), which may then contribute to tissue inflammation and late fibrosis ([@b64]).

CTGF has been described as a downstream mediator of TGF-β in the fibrotic process ([@b104]; [@b80]; [@b49]; [@b279]; [@b122]). TGF-β1-induced effects can be blocked by CTGF antisense oligonucleotides ([@b49]; [@b1]; [@b279]). However, CTGF can also exert its pro-fibrotic effects via TGF-β1-independent pathways ([@b163]; [@b16]; [@b261]; [@b158]; [@b29]) as seen for induction of CTGF by AGEs which is TGF-β independent ([@b261]). Glucose-induced collagen production was reduced by CTGF anti-sense nucleotide ([@b273]; [@b1]; [@b211]; [@b279]; [@b81]), ACEI or ARB ([@b209]; [@b283]; [@b17]; [@b212]; [@b258]), or by treatment with an AGE inhibitor ([@b260]; [@b25]). CTGF can interact with, and influence the signaling of IGF-I ([@b131]), VEGF ([@b18]), TGF-β ([@b80]) and bone morphogenic proteins (BMPs) ([@b2]). Moreover, CTGF can be cleaved by metalloproteases (MMPs) and other proteases ([@b88]).

### PDGF-β

PDGF-β is involved in structural alterations at the glomerular level. It seems that high glucose induces an early activation of a PDGF loop that in turn causes an increase of TGF-β1 gene expression, thus modulating both human mesangial cell proliferation and mesangial matrix production ([@b46]).

### VEGF

VEGF appears to be another mediator for these early and late vascular changes. Neutralizing antibodies directed against VEGF blocked vascular permeability and blood flow changes induced by elevated tissue glucose and sorbitol levels in a dosage-dependent manner ([@b40]). VEGF signaling affected GBM thickening, slit pore density, and nephrin quantity, all of which were associated with the extent of diabetic albuminuria. These effects could be blocked by a VEGF receptor inhibition ([@b239]).

### FGF

FGF is secreted by fibroblasts, macrophages and in particular endothelial cells (EC) in response to tissue injury and is important in promotion of neovascularization. Produced and stored in epiretinal membranes ([@b99]; [@b220]), FGF is a potent endothelial cell mitogen that has been proposed to play a role in proliferative diabetic retinopathy and other neovascular processes ([@b86]).

Protease systems and their regulators
-------------------------------------

### The MMP system

Metalloproteinases (MMPs) are a family of zinc-dependent enzymes with the combined ability to digest all ECM proteines: native and partially degraded fibrillar collagens, basement membrane collagens, proteoglycans, elastin, fibronectin. The gelatinase (MMP-2 and MMP-9) are two proteinases primarily responsible for breaking down type IV collagen from the BMs. These are produced by multiple vascular cell types, such as pericytes, podocytes, vascular smooth muscles cells, renal mesangial cells, fibroblasts, macrophages. The MMPs are synthesized as inactive zymogens with a pro-peptide domain that must be removed before the enzyme is active. Activation of MMPs can be induced by urokinase type (uPA) and tissue-type (tPA) plasminogen activators that cleave plasminogen into active plasmin. MMP-9, but not other MMPs, is able to upregulate biologically active proteins such as the profibrotic growth factor TGF-β ([@b213]).

A major control point in the regulation of active enzyme is inhibition of the active form by their tissue family of inhibitors. TIMPs comprise a family of four protease inhibitors (TIMP-1 to TIMP-4), which are expressed in a tissue specific pattern and regulate the function of MMPs either by inhibiting active MMPs or by controlling their activation process. Overall, all MMPs are inhibited by TIMPs once they are activated, with most of the MMPs being inhibited by TIMP-1. The gelatinases (MMP-2 and MMP-9) can form complexes with TIMPs when the enzymes are in the latent form. The complex of latent MMP-2 (pro-MMP-2) with TIMP-2 serves to facilitate the activation of pro-MMP-2 at the cell surface by MT1-MMP (MMP-14), a membrane-anchored MMP. The role of the pro-MMP-9/TIMP-1 complex is unknown.

An imbalance between MMPs and TIMPs plays an important role in ECM modeling that favors tissue fibrosis. For example, the imbalance between the MMP-2 and TIMP-2, caused primarily by an increase in TIMP-2 activity, may contribute to the pathogenesis of diabetic nephropathy ([@b84]). Decreased MMP-2 expression and activity, and up-regulated MMP-9 protein were found in the myocardium of diabetic mice with STZ-induced DCM. These alterations were corrected by ARB treatment ([@b278]). Myofibroblasts and vascular endothelial cells in PDR membranes expressed an increase in MMP-9 protein and activity ([@b3]). ProMMP-9 and activated MMP-9 levels were also significantly increased in vitreous samples in PDR patients. In addition, TIMP-1 levels were significantly increased in PDR patients. Activated MMP-9 levels in vitreous samples of PDR patients with hemorrhage were higher than those in PDR patients without hemorrhage, suggesting that activated MMP-9 might be involved in hemorrhagic transformation in these patients ([@b45]).

### The plasminogen system

Plasminogen activator (PA)/plasmin/PA inhibitor (PAI) system is involved in ECM degradation. PAI-1 may promote ECM build-up by preventing plasmin and MMPs activation ([@b157]). PAI-1 can regulate TGF-beta expression by binding to uPAR and activating the extracellular-regulated signal kinase (ERK)/MAPK pathway ([@b287]). PAI-1 plays a critical role in ECM remodeling in the kidney. Normal human kidneys do not express PAI-1 but PAI-1 is overexpressed in pathologic conditions associated with renal fibrosis including diabetic nephropathy ([@b183]; [@b83]). Reactive oxygen species mediate PAI-1 up-regulation in renal cells cultured under high glucose, hypoxia, and with TGF-beta1 ([@b133]). PAI-1 induced ECM deposition in diabetic kidney through increased ECM synthesis by TGF-beta1 up-regulation as well as through decreased ECM degradation by suppression of plasmin and MMP-2 activity ([@b133]). Impaired fibrinolysis resulting from high plasma PAI-1 can lead to excessive fibrin accumulation within vessels, resulting in atherothrombosis. Increased expression of PAI-1 was found in the arterial wall in patients with type 2 diabetes ([@b179]). This increased vascular expression of PAI-1 promotes neointima formation via accumulation of fibrin or fibrinogen as a result of inhibited clearance of platelet-fibrin thrombi. PAI-1, an acute phase protein, also has been involved in vascular inflammation ([@b5]).

[Figure 4](#fig4){ref-type="fig"} shows methods in diabetes by which pro-fibrotic growth factors may link with the protease and anti-protease systems to dysregulate ECM turnover and thus cause ECM accumulation.

![One pathogenic pathway by which high glucose in diabetes and hypertension work through prosclerotic growth factors to dysregulate ECM turnover. Both TGF-β and CTGF have been shown to induce TIMP-1 and PAI-1, resulting in reduced MMP and plasmin activity. This paradigm best applies to diabetic renal disease.](vhrm0403-575-04){#fig4}

Endothelin-1
------------

Endothelin-1 (ET-1) is a potent vasoconstrictor peptide, which can also exert pro-inflammatory, mitogenic and pro-fibrotic effects. Up-regulated by glucose, angiotensin II, TGF-β, ROS and PDGF in various renal cells ([@b301]; [@b123]; [@b124]; [@b101]; [@b98]), retinal cells ([@b28]; [@b182]; [@b290]) and cardiomyocytes, ET-1 has been linked with matrix accumulation in diabetic kidney ([@b208]; [@b87]) and cardiomyocyte hypertrophy ([@b33]), and with hemodynamic and histopathological abnormalities in diabetic retina ([@b24]; [@b241]; [@b27]). Neutralizing ET-antibodies and anti-sense oligonucleotides, as well as ET-receptor antagonist treatment reduced proteinuria and the production of ECM proteins in the kidney ([@b137]; [@b93]; [@b236]) and prevented myocardial and coronary dysfunction ([@b47]; [@b281]) in experimental diabetes.

Markers of fibrosis in biological fluids in diabetes
====================================================

In order to assess accurately the morphological changes in the target organs and the extent to which the fibrotic changes affect their function, invasive studies (tissue biopsy) is commonly required. However, biopsy is not always feasible in human tissues and is associated with obvious risks. Therefore it is highly desirable to potentially estimate the severity of organ fibrosis by measuring ECM factors in biological fluids (peripheral blood or urine). Such markers, if proven they mirror the changes in specific organs structure and function, will allow a better monitoring of the disease. Moreover, if these markers levels show changes with treatment, they will be a useful tool to evaluate the therapeutic interventions. Thus the potential clinical value of the circulating or urinary levels of several ECM components and its regulators have been tested in diabetes and its complications.

ECM formation and degradation markers
-------------------------------------

Serum aminoterminal propeptide of type III (PIIINP) or type I (PINP) procollagen and carboxyterminal propeptide of type I procollagen (PICP) are released in a stoichiometric manner with collagen type III or I molecules during collagen biosynthesis, and therefore they are considered markers of the synthesis and deposition of type III and I collagen ([@b110]; [@b199]; [@b276]). However, there is evidence that some of the PIIINP is also released during collagen degradation, because these propeptides are not completely cleaved during collagen synthesis ([@b61]). Therefore, PIIINP could reflect both synthesis and degradation of collagen.

Circulating levels of collagen have been suggested as indicators of diabetic complications. Elevated serum levels of both PIIINP and laminin were associated with the development of diabetic microangiopathy ([@b176]). Another study ([@b160]) found elevated serum PIIINP levels in type 2 diabetic subjects with peripheral vascular disease and proposed that this reflected an increase in collagen deposition in the large arteries that accompanies the development of macroangiopathy. Serum PIIINP was also increased in type 2 diabetic patients with nephropathy ([@b108]).

PICP concentration did not differ between uncomplicated type 2 diabetic patients and controls, but it was increased in complicated diabetes and related to the progression of nephropathy ([@b106]). In contrast, other investigators found decreased levels of serum PICP but increased PIIINP concentrations in subjects with proliferative retinopathy compared with those with no retinopathy ([@b9]). Similarly, hypertensive type 2 diabetic patients had higher mean levels of PIIINP than controls, and lower mean levels of PINP and PICP ([@b6]). No association between collagen markers and neuropathy was found ([@b9]).

ECM regulators as systemic fibrosis markers
-------------------------------------------

In patients with type 1 diabetes plasma and urinary TGF-β1 levels were significantly higher than in controls. The effect of metabolic control on plasma TGF-β level is controversial ([@b10]; [@b62]; [@b252]). Increased TGF-β levels in both plama and urine were found especially in relation to diabetic nephropathy ([@b185]; [@b97]). Urinary TGF-beta significantly decreased with ACEI, ARB or thiazolinediones treatment, in parallel with a decrease in albuminuria ([@b154]; [@b116]; [@b232]; [@b282]).

While it seems correlated with glycemic control ([@b113]), plasma VEGF concentration was not strongly correlated with risk factor status or microvascular disease in type 1 diabetes, nor was affected by ACE inhibition ([@b31]). Urinary VEGF concentrations were significantly higher in the diabetic groups, even at the normoalbuminuric stage, with further increase as diabetic nephropathy advanced ([@b119]).

Diabetes status is associated with dysregulation in the circulating MMP/TIMP system even in the absence of complications. Thus, serum MMP-9 and TIMP-1 levels are increased in both type 1 ([@b155]) and type 2 diabetes ([@b246]), with no changes in MMP-2 concentration. In contrast, in another study urine and plasma MMP-2 levels and plasma MMP-2 activity were all significantly elevated in type 1 diabetic patients, with urine MMP-2 correlated with higher HbA1c, longer duration of diabetes, evidence of renal hyperfiltration and the presence of microalbuminuria ([@b252]). Increased serum MMP-2 and TIMP-1 concentrations, but no elevation of MMP-9 levels, were also found in a cohort of diabetic patients with mild or no complications ([@b134]).

Some therapies have been proven efficient in reduction the plasma/serum MMPs and TIMP-1 levels in diabetic patients. Thiazolidinediones, which act via the PPARγ receptor, reduced the increase in circulating levels of MMP-9 but had no effect on circulating MMP-2. Furthermore, reductions in MMP-9 levels were associated with decrease in other inflammatory markers, such as C-reactive protein, PAI-1, IL-6, TNF-α and serum amyloid A ([@b82]; [@b151]; [@b85]).

Circulating MMP-9 and TIMP-1 could also be reduced by lipid reduction therapy (plasma LDL apheresis) in diabetic patients with end-stage renal disease and arteriosclerosis obliterans ([@b167]). Multifactorial cardiovascular risk reduction therapy with intensive glucose control and statin therapy caused significant reductions in circulating TIMP-1 levels ([@b246]). This effect was probably independent of blood pressure lowering, as the latter was relatively well controlled from the outset and did not fall significantly.

Current evidence for clinical utility of markers of fibrosis in diabetes
========================================================================

Diabetic renal disease
----------------------

Type IV collagen in the circulation or urine has been identified as a possible indicator of renal injuries, especially in early stages of diabetic nephropathy, in numerous, albeit relatively small studies ([@b275]; [@b128]; [@b284]; [@b245]). Both serum and urinary type IV collagen increased in accordance with the clinical stage of the renal disease ([@b275], [@b274]; [@b284]; [@b245]). Serum carboxy-terminal propeptide type I procollagen (P1CP) levels may also reflect the progression of diabetic nephropathy in patients with type 2 diabetes ([@b106]). In type 1 diabetes, measurement of syndecan-1 in serum has shown significant increase even at the microalbuminuric stage compared to normoalbuminuric patients ([@b240]). TGF-β levels in serum were increased in patients with diabetic nephropathy ([@b223]) and decreased with ACEI ([@b53]; [@b223]).

Urinary levels of collagen IV positively correlated with uPA, and that of fibronectin negatively correlated with PAI-1 in the diabetic patients with microalbuminuria ([@b282]). Urinary TGF-β was significantly increased in type 2 diabetic patients with micro- or macroalbuminuria. ACEI, ARB, and TZD significantly reduced urinary excretion of TGF-β in these patients ([@b97]; [@b186]; [@b154]; [@b116]; [@b232]; [@b282]).

Increasing evidence has emerged on circulating and urinary CTGF as indicators of renal disease in diabetes. Elevated plasma CTGF concentrations have been found in diabetic nephropathy. CTGF levels in the circulation correlated with urinary albumin excretion, creatinine clearance, glycemic control and duration of diabetes ([@b202]). Of note, there was a wide overlap in plasma CTGF between normoalbuminuric patients and those with diabetic nephropathy. Urinary concentrations of CTGF (U-CTGF) has been more extensively investigated than circulating CTGF, in diabetic renal disease ([@b70]; [@b196]; [@b171]). U-CTGF was correlated with clinical markers of renal disease severity (urinary albumin excretion rate and glomerular filtration rate). Furthermore, the association of U-CTGF with diabetic nephropathy was comparable with that of the established risk factors: HbA1c and systemic blood pressure. Significantly higher in patients with microalbuminuria or overt nephropathy, urinary CTGF excretion varied largely across the studies, from 1.6-fold ([@b171]) to 6-fold ([@b196]) and were 10--100-fold higher ([@b70]) in diabetic nephropathy versus normoalbuminuric subjects. Large overlaps in U-CTGF were also noted between patients and controls ([@b171]). In patients with DN, U-CTGF correlated positively with urinary albumin excretion and negatively with GFR ([@b171]). It is unclear to what extent plasma CTGF levels contribute to U-CTGF. CTGF and its fragments are predicted to be cleared from plasma by glomerular filtration.

Animal studies have shown increased CTGF mRNA in renal cortex in a very early phase of nephropathy, which paralleled an increase in plasma and U-CTGF ([@b201]). Local production of CTGF in the kidney, renal filtration of (elevated) plasma CTGF, together with tubular dysfunction and/or saturation of tubular reabsorption capacity in proteinuric patients may all be involved in increased U-CTGF ([@b171]). Interventional studies have shown that in type 1 diabetes with nephropathy, RAS blockade with ARB significantly decreased U-CTGF concentration, and this reduction was associated with a slower rate of decline in GFR in a cohort of hypertensive type 1 diabetic patients with diabetic kidney disease ([@b7]). However, plasma CTGF remained unchanged throughout the study, suggesting that circulating CTGF is at least partly independent of U-CTGF and renal dysfunction.

In diabetic patients, plasma VEGF levels were found to be positively correlated with plasma urea and urinary ACR, and urinary VEGF was positively correlated with urinary ACR and creatinine. Urinary VEGF and serum creatinine were independently correlated with urinary ACR ([@b119]). Urinary excretion of VEGF increased during the earlier stage of diabetic nephropathy and was significantly correlated with urinary albumin excretion. This suggests that urinary VEGF might be used as a sensitive marker of diabetic nephropathy and for predicting disease progression ([@b119]). In addition, another study implicated the potential of plasma VEGF as a DN marker ([@b11]).

Dysregulations in circulating and urinary MMP/TIMP systems have been found in diabetic renal disease. Thus, increased levels of plasma MMP-9 have been shown in DN patients ([@b168]; [@b293]), and were significantly reduced by ACEI treatment ([@b168]). Moreover, it seems that elevation in plasma MMP-9 may precede the onset of microalbuminuria in type 2 diabetic patients ([@b50]). Higher levels of MMP-9 were also found in the urine of type 2 diabetic patients with macroalbuminuria ([@b245]). Interestingly, urinary MMP-9 levels were elevated not only in patients with diabetic renal disease but also in their first-degree relatives when compared with healthy controls ([@b293]). It has been suggested that increased urinary MMP-2 and MMP-9 activities, but not serum MMP levels, may be sensitive markers of the extent of renal disease in type 1 diabetic patients ([@b245]). Urine MMP-2 concentrations correlated with higher HbA1c levels, longer duration of disease, evidence of renal hyperfiltration, and the presence of microalbuminuria ([@b252]).

Another study has shown a significant increase in urinary TIMP-1 in association with urinary albumin and the progress of glomerular diffuse lesions, while no correlation between serum TIMP-1 and urinary TIMP-1 was found ([@b114]). TIMP-1 was also increased in the urine in a group of nondiabetic patients with chronic renal disease and was correlated with progressive reduction in renal function, but not with proteinuria ([@b95]). In an animal model urinary protein excretion showed a significant positive correlation with glomerular and tubular TIMP-2 protein, and a negative correlation with MMP-2 expression ([@b84]).

Diabetic retinopathy
--------------------

Increased synthesis of type III collagen (serum PIIINP), reflecting deposition of matrix and BM connective tissue, has been reported in patients with DPR ([@b9]). While some investigators have found no significant differences of serum carboxy-terminal propeptide of human type I procollagen (PICP) across the differing severity of diabetic retinopathy in type 2 diabetic patients ([@b106]), others have actually observed progressively decreased levels of serum PICP, which can result in weakened vascular integrity in subjects with retinopathy ([@b9]).

Diabetic retinopathy is associated with increased concentrations of type IV collagen in serum ([@b288]; [@b127]). Although in the vitreous the NH2-terminal CTGF fragment content was increased in patients with active PDR, suggesting that it may play a pathogenic role or may represent a surrogate marker of CTGF activity in DR ([@b91]), the elevated level of plasma CTGF found in the circulation in patients with DR compared with patients without DR seems likely to be due to associated nephropathy rather than to the retinopathy itself ([@b202]). In addition, no changes in urinary CTGF were noted in DR ([@b171]).

Increased plasma levels of VEGF and Ang II were found in diabetic patients, with the highest VEGF and Ang II levels being seen among patients with pre-proliferative and proliferative retinopathy ([@b141]). The clinical utility of plasma VEGF levels after photocoagulation has yielded contradictory results ([@b140]; [@b141]).

Diabetic patients with retinopathy also displayed elevated systemic values of MMP-9 and MMP-9/TIMP-1 ratio when compared with patients without retinopathy. Logistic regression analysis identified diabetes duration firstly, and MMP-9 serum levels secondly as significant and independent variables associated with the existence of retinopathy in type 1 diabetic patients who were free of other overt vascular complications ([@b109]).

Diabetic cardiomyopathy, heart failure
--------------------------------------

A strong correlation has been reported between myocardial collagen content and serum concentration of PICP in systemic hypertension ([@b189]). Moreover, serum PICP has been found to be secreted by the heart via the coronary sinus in patients with hypertensive heart disease ([@b188]). Thus, even if these markers could be released from various other tissues in diabetes or hypertension, the measurement of serum collagen degradation products may offer a reasonable evaluation of myocardial ECM changes in diabetes. In a highly selected group of uncomplicated type 2 diabetic patients, parameters of myocardial function were positively correlated with glutathione peroxidase and serum PICP, but not with levels of angiotensin II, aldosterone or endothelin-1 ([@b76]). Serum propeptide of procollagen type I (PIP) appears an independent predictor of new heart failure episodes, readmission and death and a single serum measurement of PIP may have prognostic value in patients presenting with decompensated heart failure ([@b210]).

In hypertensive subjects, plasma TIMP-1 levels were increased and associated with LVH and LV diastolic impairment in some ([@b132]; [@b139]; [@b254]) but not all studies ([@b142]). Treatment of hypertension with ACEI has been shown to decrease TIMP-1 levels ([@b132]). Previous studies of small samples of patients with heart failure or LV dilatation have yielded inconsistent results, with both increased and decreased levels of myocardial or serum TIMP-1 being reported. ([@b138]; [@b221]). The Framingham Heart Study ([@b238]) has shown that plasma total TIMP-1 is directly related to major CVD risk factors and to echocardiographic indices of LVH, and inversely to systolic dysfunction.

It has also been suggested that elevated TIMP-1 might be a useful noninvasive marker of left ventricular diastolic dysfunction and fibrosis ([@b139]). Serum TIMP-1 concentrations over 500 ng/ml showed good specificity and positive predictive value for detecting diastolic dysfunction among untreated patients with hypertension ([@b139]). In an asymptomatic population with either diabetes or hypertension, but with no evidence of LV hypertrophy, plasma TIMP-1 negatively correlated with e' (early diastolic velocity at the annulus). This suggests that the higher circulating levels of TIMP-1 may reflect structural changes within the heart that result in diastolic dysfunction. The correlation was however stronger among the hypertensive patients when compared with the diabetic group, suggesting again that systemic hypertension may mainly mediate the TIMP-1 and diastolic dysfunction link ([@b247]).

Increased serum levels of AGEs were associated with heart stiffness in patients with type 1 diabetes, possibly mediated by the cross-linking properties of AGEs ([@b14]).

Atherosclerosis and arteriosclerosis
------------------------------------

Plasma plasminogen activator inhibitor (PAI)-1, a potent inhibitor of fibrinolysis, was elevated in a number of clinical situations that are associated with high incidence of cardiovascular disease (CVD) (obesity, hypertension, type 2 diabetes) ([@b94]).

Serum 7S-collagen levels in diabetic patients with essential hypertension were significantly higher than in normal subjects, and significantly correlated with systolic blood pressure. Thus it has been suggested that the metabolic alteration of basement membrane occurring in patients with diabetes mellitus may worsen in the presence of high systolic blood pressure ([@b289]). In hypertensive type 2 diabetic patients there were also noted an imbalance between serum MMP-1 which was decreased, and its tissue inhibitor, TIMP-1 which was not significantly changed compared to controls ([@b6]).

Diabetic patients with acute coronary syndromes showed increased plasma levels of MMP-9, TIMP-1, and TIMP-2 ([@b43]). A high percent of patients with coronary artery disease (CAD) or acute coronary syndromes (ACS) had elevated urine values of MMP-9 and TIMP-1 suggesting that these variables might be a useful marker of atherosclerotic disease ([@b60]). Plasma levels of MMP-9, TIMP-2, but not TIMP-1 were high in patients with stable CAD compared with healthy controls. However, no correlation with severity of CAD or collateralization was found ([@b248]).

In patients with premature coronary atherosclerosis, the levels of plasma MMP-9 and TIMP-1 were significantly higher, and the levels of MMP-2, MMP-3, and TIMP-2 were significantly lower than those of controls, with significant positive correlation between plasma MMP-9 levels and low-density lipoprotein (LDL)-cholesterol levels, and significant negative correlation between plasma MMP-9 levels and high-density lipoprotein (HDL)-cholesterol levels. TIMP-2 levels were negatively correlated with total cholesterol and LDL-cholesterol levels ([@b173]).

In patients with CAD the low TGF-β group had a significantly poor prognosis in terms of survival without cardiovascular events and survival without coronary interventions as compared with the high TGF-β group, while other prognoses were comparable between the two groups. These results suggest that lower plasma concentrations of TGF-β may have an adverse prognostic significance in patients with CAD ([@b243]). In another study, plasma TGF-β levels were significantly lower in patients with ischemic heart disease than they were in controls ([@b244]).

Liver fibrosis
--------------

The serum glyceraldehyde-derived AGEs level may be a useful biomarker for discriminating NASH from simple steatosis. Moreover, it correlated with adiponectin ([@b103]). Serum hyaluronic acid could identify NAFLD in patients with severe fibrosis in some ([@b214]; [@b115]) , but not all studies ([@b291]). Type IV collagen 7 s domain and type IV collagen 7s domain concentrations in the circulation have been identified as potential markers in differentiating between NASH and NAFLD ([@b214]), and between advanced and mild liver fibrosis ([@b291]). Serum levels of endothelin-1 (ET-1), an inflammatory and marker of increased endothelial tone, also showed a significant positive correlation with liver fibrosis severity in patients with NASH ([@b42]).

TIMP-1 and MMP-1 levels in serum or peripheral blood mononuclear cells (PBMCs) seem to have some value in assessing liver fibrosis. The combination of serum PDGF-BB, TIMP-1 mRNA and TIMP-1mRNA/MMP-1mRNA ratio in PBMCs was suggested as an efficient test in screening for the presence of liver fibrosis ([@b294]).

Research required in circulating and urinary markers of fibrosis in diabetes
============================================================================

Important issues appear when interpreting levels of the ECM markers and their regulators in blood or urine from diabetic patients. First, it is not yet clear whether the assessment of these markers in biological fluids provide clinically valuable information of the fibrosis process in the affected organs and whether tissue levels are reflected accurately in blood or urine. Factors such as the relative contribution of a tissue to a particular circulating marker and also the rate of clearance of the marker from the circulation and its dependence on renal function can have significant effects on its level. Nevertheless, the fact that different therapies impact upon their levels indicates that they may be involved in the pathological process.

A second issue is the presence of conditions that commonly co-exist with diabetes, such as hypertension and/or dyslipidemia, which could also influence the levels of circulating/urinary markers of fibrosis. The differentiation between the contribution of diabetes and other co-morbidities to the total level of ECM markers in blood/urine could therefore be difficult to assess.

[Figure 5](#fig5){ref-type="fig"} summarizes the main findings of circulating and urinary markers and their regulators and their potential value in diabetes complications. At this time, Type IV collagen and CTGF in plasma and urine hold promise in diabetic renal disease, MMP-9 has promise in acute coronary syndromes as does TIMP-1 and also in myocardial dysfunction. Longitudinal and large studies in appropriate populations of people with diabetes, will be needed to further investigate the possible clinical value of these and other ECM components and ECM regulators as makers for incipient or progressive diabetes complications. Ideally, such markers in their natural history and after therapy, would show predictive value independent of other common clinical variables such as hypertension, degree of glycemic control, and microalbuminuria. It is envisaged that clinically verified algorithms will be generated where automated plasma or urine measures will aid in the calculation of risk of tissue fibrosis, and related organ dysfunction. It may be that other, tissue specific measures such as BNP for the heart or liver function tests for liver fibrosis, will be useful in combination with such ECM markers. Urinary measures do appear to often be independent of circulating levels, although whether such measures have advantage over albuminuria and estimated GFR levels, remains to be determined.
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